{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:47:25Z","timestamp":1793141245342,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,1]],"date-time":"2027-06-01T00:00:00Z","timestamp":1811808000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR51749"],"award-info":[{"award-number":["R01 AR51749"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.02.020","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:39:43Z","timestamp":1776512383000},"page":"969-983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The evolving landscape of complement therapeutics in rheumatology"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7746","authenticated-orcid":false,"given":"V. Michael","family":"Holers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.02.020_bib0001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.272.5258.50","article-title":"The instructive role of innate immunity in the acquired immune response","volume":"272","author":"Fearon","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ard.2026.02.020_bib0002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0003","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41584-023-00981-x","article-title":"Complement therapeutics are coming of age in rheumatology","volume":"19","author":"Holers","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0004","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2026.02.020_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0006","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2026.02.020_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: are we there yet, or just getting started?","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ard.2026.02.020_bib0009","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fimmu.2018.01057","article-title":"Complement in the initiation and evolution of rheumatoid arthritis","volume":"9","author":"Holers","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.41948","article-title":"Association of sputum neutrophil extracellular trap subsets with IgA anti-citrullinated protein antibodies in subjects at risk for rheumatoid arthritis","volume":"74","author":"Okamoto","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0011","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-025-08713-9","article-title":"Granzyme K activates the entire complement cascade","volume":"641","author":"Donado","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ard.2026.02.020_bib0012","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1016\/j.molimm.2007.06.006","article-title":"The relative importance of local and systemic complement production in ischaemia, transplantation and other pathologies","volume":"44","author":"Li","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01893018","article-title":"Initiation of complement activation","volume":"7","author":"Lachmann","year":"1984","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.ard.2026.02.020_bib0014","doi-asserted-by":"crossref","first-page":"eabo0686","DOI":"10.1126\/scitranslmed.abo0686","article-title":"Granzyme K+ CD8 T cells form a core population in inflamed human tissue","volume":"14","author":"Jonsson","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0015","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41586-024-08395-9","article-title":"GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases","volume":"638","author":"Lan","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ard.2026.02.020_bib0016","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.imbio.2012.07.008","article-title":"The tick-over theory revisited: is C3 a contact-activated protein?","volume":"217","author":"Nilsson","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.ard.2026.02.020_bib0017","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement-MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ard.2026.02.020_bib0019","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.1073\/pnas.91.13.6123","article-title":"Agalactosyl glycoforms of IgG autoantibodies are pathogenic","volume":"91","author":"Rademacher","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ard.2026.02.020_bib0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ard.2026.02.020_bib0021","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1084\/jem.20090633","article-title":"Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D","volume":"207","author":"Takahashi","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0022","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/imr.13136","article-title":"Contributions of animal models to mechanistic understandings of antibody-dependent disease and roles of the amplification loop","volume":"313","author":"Holers","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ard.2026.02.020_bib0023","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.176.3.1305","article-title":"The central role of the alternative complement pathway in human disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0024","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ard.2026.02.020_bib0025","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","article-title":"Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets","volume":"190","author":"Xie","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ard.2026.02.020_bib0026","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000336590","article-title":"Hereditary and acquired complement component 1 esterase inhibitor deficiency: a review for the hematologist","volume":"127","author":"Cicardi","year":"2012","journal-title":"Acta Haematol"},{"issue":"61","key":"10.1016\/j.ard.2026.02.020_bib0027","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","article-title":"The role of complement in C3 glomerulopathy","volume":"67","author":"Zipfel","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0028","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.imlet.2015.11.014","article-title":"C4b-binding protein: the good, the bad and the deadly. Novel functions of an old friend","volume":"169","author":"Ermert","year":"2016","journal-title":"Immunol Lett"},{"key":"10.1016\/j.ard.2026.02.020_bib0029","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00018-016-2418-4","article-title":"Complement factor H in host defense and immune evasion","volume":"74","author":"Parente","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ard.2026.02.020_bib0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0065-2776(08)60868-8","article-title":"Control of the complement system","volume":"61","author":"Liszewski","year":"1996","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0031","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.clim.2005.10.014","article-title":"Membrane complement regulatory proteins","volume":"118","author":"Kim","year":"2006","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0032","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.molimm.2003.10.002","article-title":"Carboxypeptidase N: a pleiotropic regulator of inflammation","volume":"40","author":"Matthews","year":"2004","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0033","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.imbio.2012.07.021","article-title":"Complement dysregulation and disease: from genes and proteins to diagnostics and drugs","volume":"217","author":"de Cordoba","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.ard.2026.02.020_bib0034","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12477","article-title":"The complement factor H-related proteins","volume":"274","author":"Medjeral-Thomas","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ard.2026.02.020_bib0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-1-62703-724-2_18","article-title":"Factor H-related proteins","volume":"1100","author":"J\u00f3zsi","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ard.2026.02.020_bib0036","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3389\/fimmu.2020.01875","article-title":"The complement C3a and C3a receptor pathway in kidney diseases","volume":"11","author":"Gao","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2023.152413","article-title":"The role of C5a receptors in autoimmunity","volume":"228","author":"Schanzenbacher","year":"2023","journal-title":"Immunobiology."},{"key":"10.1016\/j.ard.2026.02.020_bib0038","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.semcdb.2017.06.009","article-title":"Molecular cell biology of complement membrane attack","volume":"72","author":"Morgan","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.ard.2026.02.020_bib0039","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/imr.13135","article-title":"Intracellular complement: evidence, definitions, controversies, and solutions","volume":"313","author":"King","year":"2023","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ard.2026.02.020_bib0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12500","article-title":"Complement component C3 - the \u201cSwiss Army Knife\u201d of innate immunity and host defense","volume":"274","author":"Ricklin","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ard.2026.02.020_bib0041","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.immuni.2012.08.002","article-title":"Regulation of humoral immunity by complement","volume":"37","author":"Carroll","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.ard.2026.02.020_bib0042","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cam4.241","article-title":"Complement anaphylatoxins as immune regulators in cancer","volume":"3","author":"Sayegh","year":"2014","journal-title":"Cancer Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0043","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.autrev.2008.06.002","article-title":"Immune complex clearance by complement receptor type 1 in SLE","volume":"8","author":"Kavai","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2026.02.020_bib0044","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0065-2776(08)60908-6","article-title":"The role of complement in B cell activation and tolerance","volume":"74","author":"Carroll","year":"2000","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0045","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/j.1462-5822.2007.00981.x","article-title":"Macrophage complement receptors and pathogen clearance","volume":"9","author":"van Lookeren Campagne","year":"2007","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.ard.2026.02.020_bib0046","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0065-2776(04)86004-8","article-title":"Innate autoimmunity","volume":"86","author":"Carroll","year":"2005","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0047","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0048","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.cell.2005.12.039","article-title":"CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens","volume":"124","author":"Helmy","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ard.2026.02.020_bib0049","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/35023175","article-title":"A role for the C3a anaphylatoxin receptor in the effector phase of asthma","volume":"406","author":"Humbles","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ard.2026.02.020_bib0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0952-7915(95)80028-X","article-title":"Structure, function and cellular expression of complement anaphylatoxin receptors","volume":"7","author":"Wetsel","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0051","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.tibs.2020.04.004","article-title":"Emerging insights into the structure and function of complement C5a receptors","volume":"45","author":"Pandey","year":"2020","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.ard.2026.02.020_bib0052","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.imbio.2012.07.015","article-title":"The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases","volume":"217","author":"Karsten","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.ard.2026.02.020_bib0053","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ard.2026.02.020_bib0054","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOP.0b013e32835df4a3","article-title":"Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases","volume":"25","author":"Nester","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.ard.2026.02.020_bib0055","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ard.2026.02.020_bib0056","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0057","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/1750743X.2024.2368342","article-title":"C5 inhibitor avacincaptad pegol treatment for geographic atrophy: a comprehensive review","volume":"16","author":"Danzig","year":"2024","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ard.2026.02.020_bib0058","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40265-024-02032-5","article-title":"Crovalimab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ard.2026.02.020_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864241279125","article-title":"Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24weeks: a model-informed analysis","volume":"17","author":"de la Borderie","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ard.2026.02.020_bib0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41590-020-00830-z","article-title":"Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease","volume":"22","author":"Ozen","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0061","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/eci.11.5","article-title":"rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency","volume":"7","author":"Varga","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0062","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2026.02.020_bib0063","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa2308695","article-title":"Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria","volume":"390","author":"Peffault de Latour","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0064","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0065","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2024026299","article-title":"Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH","volume":"145","author":"Kulasekararaj","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.ard.2026.02.020_bib0066","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0067","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","article-title":"Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"10","author":"Vlaar","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0068","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/eci.12419","article-title":"Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention","volume":"45","author":"Mastellos","year":"2015","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ard.2026.02.020_bib0069","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0070","first-page":"35","author":"Nester","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0071","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2026.02.020_bib0072","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2217\/imt-2022-0085","article-title":"Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ard.2026.02.020_bib0073","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jtct.2025.01.058","article-title":"Narsoplimab treatment for hematopoietic cell transplant associated thrombotic microangiopathy (TA-TMA) - real world outcomes from an expanded access program","volume":"31","author":"Schoettler","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ard.2026.02.020_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102687","article-title":"Local complement inhibition by selective precision-targeted therapies","volume":"98","author":"Wang","year":"2026","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0075","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1093\/jimmun\/vkaf053","article-title":"Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies","volume":"214","author":"Liu","year":"2025","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0076","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.smim.2016.05.007","article-title":"New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities","volume":"28","author":"Holers","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0077","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/art.41011","article-title":"Measuring circulating complement activation products in myeloperoxidase- and proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"71","author":"Wu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0078","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","article-title":"Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0079","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ard.2026.02.020_bib0080","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.4049\/jimmunol.2101170","article-title":"Analysis of complement gene expression, clinical associations, and biodistribution of complement proteins in the synovium of early rheumatoid arthritis patients reveals unique pathophysiologic features","volume":"208","author":"Banda","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0081","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.molimm.2022.01.011","article-title":"Lectin and alternative complement pathway activation in cutaneous manifestations of IgA-vasculitis: a new target for therapy?","volume":"143","author":"Damman","year":"2022","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0082","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00467-021-04950-y","article-title":"IgA vasculitis with nephritis: update of pathogenesis with clinical implications","volume":"37","author":"Hastings","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0083","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1523-1755.2004.00371.x","article-title":"Effects of complement factor D deficiency on the renal disease of MRL\/lpr mice","volume":"65","author":"Elliott","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2026.02.020_bib0084","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab","volume":"65","author":"El-Husseini","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0085","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ard.2026.02.020_bib0086","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40620-016-0357-7","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0087","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0088","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.ard.2026.02.020_bib0089","article-title":"Exploring complement biomarkers in suspected axial spondyloarthritis","volume":"15","author":"Misteg\u00e5rd","year":"2014","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.020_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006087","article-title":"Complement system activation is associated with spinal radiographic progression in axial spondyloarthritis after 2 years of follow-up: findings from the CONSUL RCT","volume":"11","author":"Mistegaard","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.020_bib0091","article-title":"Inhibition of complement retards ankylosing spondylitis progression","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2026.02.020_bib0092","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1002\/eji.201444560","article-title":"Complement C5a potentiates uric acid crystal-induced IL-1\u03b2 production","volume":"44","author":"An","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0093","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/nm.2543","article-title":"Identification of a central role for complement in osteoarthritis","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0094","article-title":"Increased complement 3a receptor is associated with Behcet's disease and Vogt-Koyanagi-Harada disease","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2026.02.020_bib0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/14397595.2015.1076924","article-title":"Possible participation of IgG4 in the activation of complement in IgG4-related disease with hypocomplementemia","volume":"26","author":"Sugimoto","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0096","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152915","article-title":"Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases","volume":"230","author":"Holers","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.ard.2026.02.020_bib0098","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molimm.2011.09.015","article-title":"The dual role of complement in the progression of renal disease in NZB\/W F(1) mice and alternative pathway inhibition","volume":"49","author":"Sekine","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0099","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/1744666X.2022.2054803","article-title":"Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0100","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1084\/jem.20061022","article-title":"Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction","volume":"203","author":"Girardi","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molimm.2004.07.043","article-title":"A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice","volume":"42","author":"Thurman","year":"2005","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0102","doi-asserted-by":"crossref","first-page":"763","DOI":"10.34067\/KID.0007142020","article-title":"Treatment updates in antineutrophil cytoplasmic autoantibodies (ANCA) vasculitis","volume":"2","author":"Jain","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.ard.2026.02.020_bib0103","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000435","article-title":"Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis","volume":"3","author":"Heijl","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.020_bib0104","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-Associated Vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/ki.2012.371","article-title":"Complement is crucial in the pathogenesis of ANCA-associated vasculitis","volume":"83","author":"Kallenberg","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2026.02.020_bib0106","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.ekir.2021.08.005","article-title":"Long-term renal survival in antineutrophil cytoplasmic antibody-associated glomerulonephritis with complement C3 deposition","volume":"6","author":"Oba","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ard.2026.02.020_bib0107","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/03009742.2021.1989814","article-title":"Rantap\u00e4\u00e4-Dahlqvist S, Complement activation prior to symptom onset in myeloperoxidase ANCA-associated vasculitis but not proteinase 3 ANCA associated vasculitis - A Swedish biobank study","volume":"51","author":"Johansson","year":"2022","journal-title":"Scand J Rheum"},{"key":"10.1016\/j.ard.2026.02.020_bib0108","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.kint.2023.10.013","article-title":"Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Lucientes-Continente","year":"2024","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.ard.2026.02.020_bib0109","doi-asserted-by":"crossref","DOI":"10.1172\/JCI188347","article-title":"Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research","volume":"135","author":"Poppelaars","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ard.2026.02.020_bib0110","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3389\/fimmu.2020.00525","article-title":"Animal models of ANCA associated vasculitis","volume":"11","author":"Shochet","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0111","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0112","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13075-017-1458-y","article-title":"Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway","volume":"19","author":"Miao","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.02.020_bib0113","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0114","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.020_bib0116","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0117","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","article-title":"Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis","volume":"29","author":"Benamu","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0118","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70001","article-title":"Safety of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: combined data from three clinical trials","volume":"7","author":"Merkel","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0119","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.41417","article-title":"Rheumatoid arthritis pathogenesis, prediction, and prevention: an emerging paradigm shift","volume":"73","author":"Deane","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1146\/annurev.immunol.26.021607.090244","article-title":"Immunity to citrullinated proteins in rheumatoid arthritis","volume":"26","author":"Klareskog","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0121","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0122","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1172\/JCI25422","article-title":"Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis","volume":"116","author":"Kuhn","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ard.2026.02.020_bib0123","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/art.24622","article-title":"Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways","volume":"60","author":"Trouw","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.020_bib0124","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ni.3579","article-title":"Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease","volume":"18","author":"Pfeifle","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0125","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0126","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0127","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0128","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.ard.2026.02.020_bib0129","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0161-5890(99)00113-3","article-title":"Complement activation and inhibition in experimental models of arthritis","volume":"36","author":"Linton","year":"1999","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0065-2776(04)82005-4","article-title":"The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease","volume":"82","author":"Monach","year":"2004","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0131","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.10183","article-title":"Local production of complement proteins in rheumatoid arthritis synovium","volume":"46","author":"Neumann","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.020_bib0132","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ard.2026.02.020_bib0133","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2174\/1874312901105010107","article-title":"The synovium in rheumatoid arthritis","volume":"5","author":"Hitchon","year":"2011","journal-title":"Open Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1876894601103010001","article-title":"Activation of complement alternative pathway in rheumatoid arthritis: implications in peripheral neutrophils functions","volume":"3","author":"Paoliello-Paschoalato","year":"2014","journal-title":"Open Autoimmun J"},{"key":"10.1016\/j.ard.2026.02.020_bib0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03589-1","article-title":"Analysis of human factor H-related gene and protein expressed in rheumatoid arthritis synovium identifies a novel mechanism promoting dysregulated complement pathway activation","volume":"15","author":"Banda","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2026.02.020_bib0136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(02)00275-3","article-title":"Arthritis critically dependent on innate immune system players","volume":"16","author":"Ji","year":"2002","journal-title":"Immunity"},{"key":"10.1016\/j.ard.2026.02.020_bib0137","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.4049\/jimmunol.179.6.4101","article-title":"Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway","volume":"179","author":"Banda","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0138","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.4049\/jimmunol.1203271","article-title":"Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis","volume":"190","author":"Banda","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0139","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.4049\/jimmunol.0901826","article-title":"Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice","volume":"183","author":"Banda","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0140","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4049\/jimmunol.1102310","article-title":"Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice","volume":"188","author":"Banda","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0141","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/art.40490","article-title":"Modulation of inflammatory arthritis in mice by gut microbiota through mucosal inflammation and autoantibody generation","volume":"70","author":"Jubair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0142","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.molimm.2008.01.036","article-title":"Complement receptor CR2\/CR1 deficiency protects mice from collagen-induced arthritis and associates with reduced autoantibodies to type II collagen and citrullinated antigens","volume":"45","author":"Kuhn","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0143","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.4049\/jimmunol.175.8.5379","article-title":"A critical role for complement C3d and the B cell coreceptor (CD19\/CD21) complex in the initiation of inflammatory arthritis","volume":"175","author":"Del Nagro","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0144","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","article-title":"Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation","volume":"46","author":"Vergunst","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.02.020_bib0145","first-page":"301","article-title":"Results of a phase 2b study of the humanized anti-C5 antibody eculizumab in patients with rheumatoid arthritis","volume":"63","author":"Mojcik","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0146","doi-asserted-by":"crossref","first-page":"e4238","DOI":"10.1097\/MD.0000000000004238","article-title":"Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: a retrospective study in 112 patients","volume":"95","author":"Bouiller","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ard.2026.02.020_bib0147","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.abd.2021.11.009","article-title":"Systemic disease in leukocytoclastic vasculitis: a focus on direct immunofluorescence findings","volume":"98","author":"Ertekin","year":"2023","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0148","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0738-081X(99)00062-0","article-title":"Urticarial vasculitis","volume":"17","author":"Black","year":"1999","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0149","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/03009742.2022.2047311","article-title":"Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis","volume":"52","author":"Conticini","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0150","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1016\/j.molimm.2009.04.029","article-title":"Complement in human diseases: lessons from complement deficiencies","volume":"46","author":"Botto","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0151","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/jcm10040626","article-title":"Expanding the role of complement therapies: the case for lupus nephritis","volume":"10","author":"Li","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002079","article-title":"Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility","volume":"7","author":"Zhao","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ard.2026.02.020_bib0153","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/rheumatology\/kes218","article-title":"Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis","volume":"51","author":"Wang","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.020_bib0154","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.40747","article-title":"Association of blood concentrations of complement split product iC3b and serum C3 with systemic lupus erythematosus disease activity","volume":"71","author":"Kim","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/art.1780350109","article-title":"Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy","volume":"35","author":"Buyon","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.02.020_bib0156","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1177\/0961203311415561","article-title":"Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis","volume":"20","author":"Sato","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.ard.2026.02.020_bib0157","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1523-1755.2001.00492.x","article-title":"Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages","volume":"59","author":"Hill","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2026.02.020_bib0158","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5","volume":"93","author":"Wang","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ard.2026.02.020_bib0159","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4049\/jimmunol.164.2.786","article-title":"Modulation of renal disease in MRL\/lpr mice genetically deficient in the alternative complement pathway factor B","volume":"164","author":"Watanabe","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0160","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/eji.200526327","article-title":"C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist","volume":"35","author":"Bao","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0161","first-page":"2286","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.020_bib0162","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0163","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0164","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/318201","article-title":"Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome","volume":"68","author":"P\u00e9rez-Caballero","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ard.2026.02.020_bib0165","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/jmg.40.9.676","article-title":"Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries","volume":"40","author":"Neumann","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.ard.2026.02.020_bib0166","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","article-title":"Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease","volume":"12","author":"Caprioli","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ard.2026.02.020_bib0167","doi-asserted-by":"crossref","first-page":"12966","DOI":"10.1073\/pnas.2135497100","article-title":"Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome","volume":"100","author":"Richards","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ard.2026.02.020_bib0168","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2026.02.020_bib0169","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1136\/jmg.2004.019083","article-title":"Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome","volume":"41","author":"Fremeaux-Bacchi","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.ard.2026.02.020_bib0170","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1681\/ASN.2004050380","article-title":"Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome","volume":"16","author":"Dragon-Durey","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ard.2026.02.020_bib0171","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000314579","article-title":"Thrombotic microangiopathies: from animal models to human disease and cure","volume":"169","author":"Caprioli","year":"2011","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.ard.2026.02.020_bib0172","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.020_bib0173","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s13075-016-1147-2","article-title":"The association of low complement with disease activity in systemic sclerosis: a prospective cohort study","volume":"18","author":"Esposito","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.02.020_bib0174","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2026.02.020_bib0175","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ard.2026.02.020_bib0176","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the pathophysiology of the antiphospholipid syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.02.020_bib0177","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ard.2026.02.020_bib0178","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ard.2026.02.020_bib0179","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.ard.2026.02.020_bib0180","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/JND-230168","article-title":"Contribution of complement, microangiopathy and inflammation in idiopathic inflammatory myopathies","volume":"11","author":"Honda","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.ard.2026.02.020_bib0181","doi-asserted-by":"crossref","first-page":"rkaf007","DOI":"10.1093\/rap\/rkaf007","article-title":"Complement proteins in axial spondyloarthritis: associations with disease activity and TNFi treatment response in a multicentre RCT","volume":"9","author":"Mistegaard","year":"2025","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.ard.2026.02.020_bib0182","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006019","article-title":"Serum calprotectin and complement factor C3 are superior biomarkers of inflammation in early psoriatic arthritis as compared with C-reactive protein","volume":"11","author":"Ishchenko","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.020_bib0183","first-page":"23","article-title":"Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment","volume":"30","author":"Chimenti","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2026.02.020_bib0184","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fphar.2017.00010","article-title":"C5a regulates IL-1\u03b2 production and leukocyte recruitment in a murine model of monosodium urate crystal-induced peritonitis","volume":"8","author":"Khameneh","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ard.2026.02.020_bib0185","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1038\/s41598-022-08311-z","article-title":"Natural antibodies and CRP drive anaphylatoxin production by urate crystals","volume":"12","author":"Wessig","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ard.2026.02.020_bib0186","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41590-019-0503-1","article-title":"Stealth\u2019 corporate innovation: an emerging threat for therapeutic drug development","volume":"20","author":"Mastellos","year":"2019","journal-title":"Nat Immunol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T20:30:55Z","timestamp":1780864255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726001354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":186,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496726001354"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.020","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The evolving landscape of complement therapeutics in rheumatology","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}